Replimune Group (NASDAQ:REPL) Director Joseph Slattery Sells 5,200 Shares of Stock

Replimune Group, Inc. (NASDAQ:REPL) Director Joseph Slattery sold 5,200 shares of the company’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $21.80, for a total value of $113,360.00. Following the completion of the sale, the director owned 1,467 shares of the company’s stock, valued at $31,980.60. This represents a 78.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Replimune Group Price Performance

REPL opened at $23.28 on Wednesday. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of -8.34 and a beta of 0.93. The company has a current ratio of 7.11, a quick ratio of 6.90 and a debt-to-equity ratio of 0.59. Replimune Group, Inc. has a 12-month low of $1.50 and a 12-month high of $23.41. The business’s fifty day simple moving average is $14.39 and its 200-day simple moving average is $9.82.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.24. On average, equities research analysts anticipate that Replimune Group, Inc. will post -2.40 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price target for the company in a report on Friday, August 7th. Wolfe Research raised shares of Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a research note on Monday, October 5th. Leerink Partners lifted their price objective on shares of Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. Finally, Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Replimune Group has an average rating of “Moderate Buy” and a consensus price target of $14.33.

Hedge Funds Weigh In On Replimune Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Essential Partners LLC raised its holdings in Replimune Group by 562,400.0% in the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after purchasing an additional 5,624 shares in the last quarter. Allworth Financial LP bought a new stake in shares of Replimune Group in the 2nd quarter valued at about $62,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Replimune Group in the 3rd quarter worth approximately $64,000. Legal & General Group Plc purchased a new position in shares of Replimune Group in the 2nd quarter worth approximately $85,000. Finally, WINTON GROUP Ltd purchased a new position in shares of Replimune Group in the 2nd quarter worth approximately $115,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.